Premier Alternatives

IMBiologics (KRX: 493280)

Suwon-si, South Korea · Founded 2020 · Publicly Held

IMBiologics Corp is a next-generation biopharmaceutical company developing antibody therapeutics. IMBiologics (KRX: 493280) is based in Suwon-si, South Korea and was founded in 2020. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $262 million (Mar 2026). It has raised $99.1 million.

Last price · $/share
—
Implied valuation
$261.7M
Total raised
$99.1M
Last round
—
No prints on record

No secondary trades in IMBiologics (KRX: 493280) shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.

Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of IMBiologics (KRX: 493280) with a free account
  • ·The complete investor list: 22 names
  • ·Watch IMBiologics (KRX: 493280): the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Where IMBiologics (KRX: 493280) prices come from

Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of IMBiologics (KRX: 493280) stock.